BBOTHealthcare · BiotechnologyBBOT Stock Forecast: Bridgebio Oncology Therapeutics, Inc. Price Predictions for 2026-2027
The 11 Wall Street analysts covering Bridgebio Oncology Therapeutics, Inc. hold a median 12-month price target of $24 — +184.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 13 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
BBOT stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Bridgebio Oncology Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (68): The share price has been relatively steady.
Growth (9): Sales and profits are flat, shrinking, or growing more slowly than they were.
The rank is the raw material. Whether the rules would actually own Bridgebio Oncology Therapeutics, Inc. — and when they’d sell — is the membership.
BBOT stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on BBOT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +184.8% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 8 July 2026 | JP Morgan | Initiates | Overweight | $27 |
| 8 July 2026 | JP Morgan | Initiates | Overweight | — |
| 22 June 2026 | Oppenheimer | Assumes | Outperform | $22 |
| 11 May 2026 | Canaccord Genuity | Initiates | Buy | — |
| 6 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 11 Feb 2026 | Stifel | Initiates | Buy | — |
| 9 Jan 2026 | Raymond James | Initiates | Outperform | — |
| 11 Dec 2025 | Wedbush | Reiterates | Outperform | — |
| 5 Dec 2025 | Morgan Stanley | Initiates | Overweight | — |
| 25 Nov 2025 | Wedbush | Reiterates | Outperform | — |
| 13 Nov 2025 | Oppenheimer | Maintains | Outperform | — |
| 17 Sept 2025 | Leerink Partners | Initiates | Outperform | — |
| 15 Sept 2025 | HC Wainwright & Co. | Initiates | Buy | — |
| 4 Sept 2025 | Oppenheimer | Initiates | Outperform | — |
| 18 Aug 2025 | Wedbush | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
BBOT analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Bridgebio Oncology Therapeutics, Inc. (BBOT) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −1.9×
- Price / sales
- —
- Price / book
- 1.8×
- EV / EBITDA
- −2.4×
Cheaper than 84% of US stocks
Cheaper than 49% of US stocks
Cheaper than 73% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −62.2%
- Return on assets
- −37.2%
- Dividend yield
- —
Higher than 18% of US stocks
Higher than 11% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
BBOT vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BBOT appears on the weeks it earns a place.
Frequently asked questions about BBOT stock
What is the BBOT stock price forecast for 2026-2027?
The 11 Wall Street analysts covering Bridgebio Oncology Therapeutics, Inc. have a median 12-month price target of $24, with estimates ranging from $18 to $41. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is BBOT stock a buy right now?
Of the 11 analysts covering Bridgebio Oncology Therapeutics, Inc., 11 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Bridgebio Oncology Therapeutics, Inc. 13 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank BBOT?
As at 1 Aug 2026, Bridgebio Oncology Therapeutics, Inc. ranks 13 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (68 of 100).
Will BBOT stock go up?
No one can know that. What the data says: the median 12-month target from 11 analysts implies +184.8% from the last close, and Ticker Nerd's factor model ranks Bridgebio Oncology Therapeutics, Inc. 13 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the BBOT stock forecast for 2030?
No analyst covering Bridgebio Oncology Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BBOT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $18 to $41 over the next 12 months.
What does Bridgebio Oncology Therapeutics, Inc. do?
BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing small molecule therapeutics targeting RAS and PI3Kα pathway cancers. The company specializes in precision oncology by creating innovative approaches to address historically difficult-to-drug targets, including direct KRAS inhibitors that bind to both active and inactive protein states, PI3Kα:RAS interaction breakers designed to block specific signaling cascades while minimizing metabolic side effects, and pan-KRAS inhibitors targeting multiple KRAS mutations.
About Bridgebio Oncology Therapeutics, Inc.
BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing small molecule therapeutics targeting RAS and PI3Kα pathway cancers. The company specializes in precision oncology by creating innovative approaches to address historically difficult-to-drug targets, including direct KRAS inhibitors that bind to both active and inactive protein states, PI3Kα:RAS interaction breakers designed to block specific signaling cascades while minimizing metabolic side effects, and pan-KRAS inhibitors targeting multiple KRAS mutations. BridgeBio Oncology Therapeutics currently has multiple programs in clinical development, including candidates for non-small cell lung cancer, colorectal cancer, and breast cancer. Originally established as a subsidiary of BridgeBio Pharma in 2016, the company became a standalone public entity in 2025 through a business combination. Based in South San Francisco, BridgeBio Oncology Therapeutics applies advanced understanding of RAS signaling biology to rational drug design, aiming to deliver well-tolerated medicines with greater efficacy and safety for patients with cancers driven by the two most prevalent oncogenes in human tumors.
CEO Mr. Eli M. Wallace Ph.D. · 106 employees · United States · https://bbotx.com